India's economic engine is revving up, but navigating the global headwinds requires sharp strategy. The rupee's recent volatility against the dollar underscores the complexities facing Indian businesses, impacting everything from import-export trade to domestic inflation. This week alone, we've seen significant shifts in the IT sector, with major players announcing restructuring and a renewed focus on AI-driven solutions. Meanwhile, the burgeoning startup ecosystem continues to attract substantial funding, despite a cautious global investor sentiment. The government's recent policy announcements on infrastructure development and digitalization are poised to further shape the business landscape, creating both opportunities and challenges for entrepreneurs and established corporations alike. Understanding these market dynamics is crucial for success in today's rapidly evolving Indian economy. Stay informed with Abtak.com for the latest insights and analysis on key sectors including finance, manufacturing, and technology – empowering your business decisions in a dynamic market. Explore the complete business news section now to stay ahead of the curve.
Ahmedabad: Zydus Lifesciences has expanded its presence in the U.S. generics market with a key regulatory approval for a widely used diabetes treatment. Zydus Lifesciences Limited has received final approval from the United States Food and Drug Administration for Dapagliflozin Tablets in 5 mg and 10 mg strengths. This approval enables the company to enter the U.S. market with a generic version of the drug, broadening its portfolio in a high-demand therapeutic category. With the approval, Zydus becomes eligible for 180 days of shared generic drug exclusivity for Dapagliflozin Tablets. This limited-period exclusivity offers a strategic advantage, allowing the company to establish market presence with reduced competition in the initial launch phase. The opportunity is particularly significant given the drug's established demand profile in the U.S. Dapagliflozin is a sodium-glucose cotransporter 2 inhibitor used alongside diet and exercise to improve glycaemic control in adults with type 2 diabetes. According to details in the company's release, the drug recorded annual sales of USD 10.2 billion in the United States as of February 2026, highlighting the scale of the opportunity for generic manufacturers. The company will manufacture the approved tablets at its formulation facility located in the Special Economic Zone in Ahmedabad. This aligns with its strategy of leveraging domestic manufacturing capabilities to serve regulated global markets. Zydus also highlighted its broader pipeline strength, with 436 approvals and 505 abbreviated new drug applications filed since the start of its filing program. The latest approval reinforces Zydus Lifesciences' ongoing focus on expanding its generics footprint and addressing large therapeutic segments such as diabetes.
New Delhi [India], July 16 (ANI): The Indian government expressed regret on Tuesday over the reported demolition of the ancestral property of celebrated filmmaker and writer Satyajit Ray in Mymensingh, Bangladesh and expressed its willingness to extend cooperation in its restoration. "We note with profound regret that the ancestral property of noted filmmaker and litterateur Satyajit Ray in Mymensingh, Bangladesh, belonging to his grandfather and eminent litterateur, Upendra Kishor Ray Chowdhury, is being demolished," the Ministry of External Affairs said. Also Read | India Urges Bangladesh ...Read More >
Hyderabad: Overdependence on white rice, refined grains and added sugars is fuelling a surge in diabetes and obesity among Indians, according to an ICMR-INDIAB survey. Telangana reflects the same dietary risks as the rest of the country. The study, published in Nature Medicine, found that more than 62 per cent of daily calories in Indian diets come from low-quality carbohydrates, while protein intake remains low and saturated fat consumption exceeds recommended levels in most states. In Telangana, high reliance on refined cereals and inadequate protein has been linked to an elevated risk of t ...Read More >
Bengaluru: Biocon Limited has achieved a regulatory milestone in the United States, reinforcing its presence in the global diabetes treatment market. Biocon Pharma Limited, a subsidiary of Biocon Limited, has received approval from the U.S. Food and Drug Administration for Dapagliflozin Tablets in 5 mg and 10 mg strengths. The approval enables the company to market the drug for adults with type 2 diabetes mellitus, expanding its footprint in one of the world's largest pharmaceutical markets. The approved drug is indicated as an adjunct to diet and exercise to improve glycemic control in adul ...Read More >
Mumbai (Maharashtra) [India], August 26: Abbott, the global healthcare company, today announced the launch of the FreeStyle Libre 2 Plus sensor, Abbott's latest addition to the FreeStyle Libre sensor portfolio. This innovative device offers automatic glucose readings every minute straight to your phone, empowering people with diabetes to manage their condition with confidence, precision, and ease. People living with diabetes can see their glucose readings, without having to scan, and receive alerts automatically on their compatible[3] smartphone when low glucose levels [4] or high glucose leve ...Read More >
BusinessWire India Mumbai (Maharashtra) [India], August 26: Abbott, the global healthcare company, today announced the launch of the FreeStyle Libre 2 Plus sensor, Abbott's latest addition to the FreeStyle Libre sensor portfolio. This innovative device offers automatic glucose readings every minute straight to your phone, empowering people with diabetes to manage their condition with confidence, precision, and ease. People living with diabetes can see their glucose readings, without having to scan, and receive alerts automatically on their compatible[3] smartphone when low glucose levels [4] ...Read More >
New Delhi, July 14 (SocialNews.XYZ) Dietary approaches like intermittent energy restriction, time-restricted eating, and continuous energy restriction can all improve blood sugar levels and body weight in people with obesity and type 2 diabetes, according to a study. Although researchers identified improved HbA1c levels, and adverse events were similar across the three groups, the IER group showed greater advantages in reducing fasting blood glucose, improving insulin sensitivity, lowering triglycerides, and strengthening adherence to the dietary interventions. IER typically involves periods ...Read More >
New Delhi, Sep 26 (PTI) Indian Pharmaceutical Alliance (IPA) on Friday said US President Donald Trump's move to impose 100 per cent import tariffs on pharmaceutical drugs from October 1 will impact only patented and branded products, not generic medicines. Reacting to the development, IPA Secretary General Sudarshan Jain said in a statement, "It is not applicable to generics medicines." Trump's statement refers to patented and branded products supplied to US, he added. In his post on social media platform Truth Social, Trump wrote, "Starting October 1st, 2025, we will be imposing a 100% Tari ...Read More >
New Delhi: US President Donald Trump's decision to impose 100% tariffs on branded and patented drug exports has shaken Indian pharmaceutical markets, despite most of India's $10 billion US sales being in generics. The uncertainty lies in whether complex generics and specialty medicines will be included, a move that could directly impact leading players like Sun Pharma, Dr. Reddy's, Cipla, Zydus Lifesciences, and others. Stocks Facing Highest Exposure Dr. Reddy's emerges as the most vulnerable, with 47% of its earnings tied to the US market, projected at $1.5 billion in FY26. Sun Pharma follo ...Read More >
Data reveals that hypertension and diabetes rates among Army JCOs and other ranks are significantly lower than national averages, prompting further investigation into preventative measures and lifestyle factors. IMAGE: Kindly note that this image has been posted for representational purposes only. Photograph: Indian Army/ANI Photo Key Points The prevalence of hypertension and diabetes in the Indian Army's junior ranks is nearly half that of the general population, as indicated by the National Fa ...Read More >
New Delhi [India], September 26 (ANI): India's pharmaceutical exports are not expected to face a major impact following the recent announcement of a 100 per cent tariff on branded and patented pharmaceutical products by the US, said Sudarshan Jain, General Secretary of the Indian Pharmaceutical Alliance (IPA). Speaking to ANI on Friday, Jain said that India's exports to the US primarily consist of generic drugs and active pharmaceutical ingredients (APIs), which are not covered under this tariff. "This [100 per cent tariff on imported pharmaceutical drugs] is applicable to patented branded p ...Read More >
A ₹1,000 crore market is set to grow 5x to ₹5,000 crore by 2030 as prices drop 40-50% post patent expiry. Three early movers are taking sharply different routes -- low-cost, premium, and partnerships in a high-stakes land grab. The Indian market for Glucagon-Like Peptide-1 (GLP-1) therapies is currently at an inflection point and is poised for strong expansion. The current market size for anti-obesity and diabetes GLP-1 drugs in India, as of 2025, is estimated to be between ₹1,000-1,200 cr ...Read More >
New Delhi, Jul 3 (PTI) Adopting a healthier lifestyle is more effective than using the anti-diabetes drug metformin, with the benefits persisting over 20 years later, according to a study. The US Diabetes Prevention Program, launched in 1996, enrolled 3,234 patients with prediabetes from 30 institutions across 22 states. The study aimed to compare the benefits of metformin and a lifestyle modification that included exercise and a healthy diet. Researchers from The University of New Mexico, US, found that making lifestyle changes lowered the development of diabetes by 24 per cent, while the a ...Read More >
Mumbai: Less than a month after Ozempic maker Novo Nordisk announced it is cutting its global workforce as part of a restructuring plan, the layoffs have hit Indian employees in Bengaluru. Junior- to mid-level employees across functions such as sales and marketing, as well as those in the company's global business services (GBS) hub, which works with its global teams, have been impacted, according to at least three people aware of the development. "At least 100-150 will be retrenched from the commercial unit, which largely includes sales and marketing roles. They are expected to be in junior ...Read More >
New Delhi [India], April 1 (ANI): The Government of India on Thursday released details on the GLP -1 Drugs' use, risks, and regulation, according to an official press release. Diabetes is a chronic disease that occurs when the pancreas does not produce adequate insulin, or when the body cannot effectively use the insulin it produces, leading to high blood sugar. If left untreated, it can lead to complications like blindness, kidney failure, heart attacks, stroke and lower limb amputation. Insulin and glucagon are hormones produced by the pancreas that regulate blood sugar (glucose) levels. I ...Read More >
New Delhi, Dec 17 (PTI) Drug firm Granules India on Tuesday said its subsidiary has received approval from the US health regulator for a generic medication used to treat attention-deficit hyperactivity disorder. Granules Pharmaceuticals, Inc (GPI) has received approval from the US Food & Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for Lisdexamfetamine Dimesylate chewable tablets, the drug firm said in a statement. The approved drug is available in multiple strengths; 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, and 60 mg, it added. The company's product is the generic ...Read More >
Delhi Police have dismantled a large interstate operation manufacturing and distributing fake life-saving drugs, seizing counterfeit medications and exposing a complex network of fraudulent GST firms used to launder the illicit proceeds. Photograph: Yves Herman/ReutersKey PointsDelhi Police busted an interstate racket manufacturing and supplying spurious life-saving medicines, arresting six people.Counterfeit drugs worth approximately Rs 2 crore were seized, including fake versions of medicines ...Read More >
New Delhi [India], August 25 (ANI): India's contract research, development, and manufacturing organisation (CRDMO) sector is emerging as one of the most dynamic growth stories in the global pharmaceutical landscape. According to a recent Jefferies India report, the country's CRDMO, which has already reached revenues of around USD 3 billion, has grown at a compound annual growth rate (CAGR) of 14 per cent over the past five years. The report highlights that India's CRDMO industry has caught the attention of global investors, with its market capitalization now standing at USD 40-50 billion. Whi ...Read More >
New Delhi [India], September 30 (ANI): The Central Drugs Standard Control Organisation (CDSCO) has approved Danish drugmaker Novo Nordisk's once-a-week injection for patients suffering from Type 2 diabetes. Also Read | Durga Puja 2025: PM Narendra Modi Participates in Durga Puja Celebrations in Delhi's CR Park on Occasion of Maha Ashtami, Prays for Everyone's Happiness and Wellbeing (See Pics). In a statement provided to ANI, Novo Nordisk has stated that Ozempic is intended for individuals with Type 2 diabetes and will be available only upon a doctor's prescription. "Ozempic is meant for pe ...Read More >
Thiruvananthapuram: Union Minister Suresh Gopi stirred controversy on Tuesday by claiming that those elected by "corpses" are now serving the state. Speaking at a neighbourhood meet called "Kalungu" in Idukki district, he alleged that cadavers from 25 years ago had cast votes in Kerala elections. Media reports have previously highlighted incidents of deceased voters being listed as active in Kerala's voter list, he said, while indirectly referring to the accusations of "scientific rigging " against the Left parties. The minister was responding to allegations of voter fraud in Thrissur consti ...Read More >
New Delhi [India], April 1 (ANI): The Government of India on Thursday released details on the GLP -1 Drugs' use, risks, and regulation, according to an official press release. Diabetes is a chronic disease that occurs when the pancreas does not produce adequate insulin, or when the body cannot effectively use the insulin it produces, leading to high blood sugar. If left untreated, it can lead to complications like blindness, kidney failure, heart attacks, stroke and lower limb amputation. Also Read | Patna Shocker: Woman Drugged With Sedative-Laced Drink and Gang-Raped on Pretext of Job Prom ...Read More >
Thiruvananthapuram, June 27 (UNI) Amid rising cases of diabetes, over 5 crore Indians remain undiagnosed, prompting urgent calls for regular screening and lifestyle changes. India faces an alarming diabetes prevalence of 11.4 per cent, with over 10 crore people currently living with the condition, Dr Naresh Purohit, Advisor for the National Programme for Prevention and Control of Diabetes, said. Quoting his recent scientific report published in the Australian Journal of Public Health, acclaimed physician pointed out that God's own country, 'Kerala', is witnessing a dramatic demographic shift ...Read More >
Bengaluru: Alembic Pharmaceuticals, Inc., the U.S. subsidiary of Alembic Pharmaceuticals Ltd., has acquired Utility Therapeutics Ltd. ("Utility") in a $12 million deal to strengthen its presence in the U.S. market. Alembic will begin the commercialization of Utility's recently FDA approved product Pivya® (pivmethecillam) for the treatment of uncomplicated urinary tract infections. Pivya® was approved by the FDA in April 2024. Commenting on the acquisition, Mr. Pranav Amin, Managing Director of Alembic Pharmaceuticals Limited, said: "This acquisition gives us a strategic entry into the special ...Read More >
Surat (Gujarat) [India], August 21: KP Group, a leading name in India's renewable energy sector, is stepping up its expansion with a clear goal of reaching 10 GW capacity by 2030. With projects already underway in Gujarat, the Group is working on projects in Rajasthan, Madhya Pradesh, Odisha, Andhra Pradesh and Maharashtra, supported by a strong order book and government partnerships. KP Group has signed memoranda of understanding with Gujarat, Odisha, Rajasthan and Madhya Pradesh for over 2.6 GW of renewable projects, while exploring new opportunities in other states. The Group has already e ...Read More >
MUMBAI, Sept 25 (Reuters) - Eli Lilly (LLY.N), opens new tab plans to bring its experimental oral weight-loss drug orforglipron to India as it sees market potential in the world's most populous nation, a senior executive said on Thursday. "I do think there is promise for products like that (orforpligron) in India, if it does get approved," Winselow Tucker, Lilly India's president said at an event in Mumbai. Tucker, however, did not indicate when Lilly plans to launch the drug. The drugmaker ha ...Read More >
Gail (India) jumped 5.71% to Rs 153.55 after the company said that it has entered into a long-term charter party agreement with Alpha Gas, a leading Greek shipping major, for the LNG carrier "Energy Fidelity." The charter party agreement was executed between GAIL and Pantheon Maritime Services, a Singapore based affiliate of Alpha Gas. The LNG carrier Energy Fidelity, with a cargo capacity of 174,000 cubic meters, is equipped with two-stroke propulsion system, complemented by advanced air lubrication technology and shaft generators, collectively enhancing fuel efficiency and significantly re ...Read More >
India Diabetes Market: By Type; By Treatment Type; By Doses Form; Route of Administration; By End User; By Distribution Channel; Supplier Landscape; 2025-2034 The India diabetes market attained a value of approximately INR 316.00 Billion in 2024. The market is projected to grow at a compound annual growth rate (CAGR) of 16.00% during the forecast period of 2025-2034, reaching an estimated value of around INR 1394.01 Billion by 2034. The rising prevalence of diabetes, driven by sedentary lifestyles, changing dietary habits, and increasing obesity rates, is contributing significantly to the mar ...Read More >
Bengaluru : Emcure Pharmaceuticals Ltd. ("Emcure") and Sanofi India Limited ("SIL") today entered into an exclusive distribution and promotion agreement for SIL's oral anti-diabetic (OAD) products in India, effective immediately. Emcure will exclusively distribute and promote the Company's OAD range of products that include well-established brands like Amaryl® and Cetapin®. While SIL will continue to own and manufacture these brands across Sanofi's plants in India and internationally, Emcure will leverage its strengths to engage healthcare professionals and expand reach of these therapeutic ...Read More >
Ahmedabad -- Senores Pharmaceuticals Limited today announced that it has entered into a definitive agreement to acquire 100% equity stake in Apnar Pharma Private Limited ("Apnar Pharma"), along with the acquisition of five Abbreviated New Drug Applications (ANDAs), marking a significant milestone in Senores' growth strategy across regulated pharmaceutical markets. Apnar Pharma, incorporated on December 12, 2014, is a privately held pharmaceutical company engaged in the licensing, development, and manufacturing of generic formulations for regulated markets including the United States, the Unit ...Read More >
Nagpur: As the world observes World Environment Day 2025 with the pressing theme "Ending Plastic Pollution Globally", doctors from various specialities in Nagpur are voicing serious concerns about the direct impact of plastic waste and broader environmental degradation on human health. From diabetes and heart disease to childhood ailments and breathing disorders, experts warn that toxins from plastics and pollution are silently driving a modern health crisis.Veteran diabetologist Dr Sunil Gupta pointed out that microplastics and endocrine-disrupting chemicals (EDCs) found in plastic packaging, ...Read More >
Lucknow: Senior Samajwadi Party leader and former minister Gayatri Prajapati was attacked by a fellow inmate inside Lucknow Jail on Tuesday. The scuffle took place within the jail premises, after which prison authorities launched an internal inquiry. According to a statement issued by Dr Ramdhani, DIG Prisons, Lucknow Range, the incident occurred after Prajapati allegedly used abusive language towards another inmate, Vishwas Rajput. In response, Vishwas attacked Prajapati using a sharp object inside the cell. DIG Prisons clarified that the incident was not premeditated and dismissed any spec ...Read More >